Results 101 to 110 of about 146,874 (392)

From Design to Outcome: The Role of Bi‐ and Multifunctional Ligands in Modern Therapeutics

Advanced Therapeutics, EarlyView.
This review highlights the innovative use of bi‐ and multifunctional ligands for precision therapeutics. From strategic linker design to bioorthogonal conjugation and nanoscaffold integration, these approaches enable precise targeting, high‐resolution receptor mapping, and enhanced drug delivery.
Célia Bouacha, Séverine Denoyelle, Sonia Cantel   +2 more
wiley   +1 more source

Clinical and molecular characterization of HER2 amplified-pancreatic cancer [PDF]

, 2013
<p>Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome ...
Biankin, A.V., Chang, D.K., Chantrill, L., Chin, V., Chou, A., Cowley, M.J., Gill, A.J., Goldstein, D., Grimmond, S.M., Humphris, J., Johns, A.L., Kassahn, K.S., Mead, R., Miller, D.K., Morey, A.L., Musgrove, E.A., Nagrial, A.M., Nones, K., Pajic, M., Patch, A.M., Pearson, J.V., Pinese, M., Rooman, I., Samra, J.S., Toon, C.W., Waddell, N., Wasan, H., Wu, J.   +27 more
core   +3 more sources

Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Statins are hypothesized to reduce the risk of cardiotoxicity associated with anthracyclines and trastuzumab. Our aim was to study the association of statin exposure with hospitalization or emergency department visits (hospital presentations ...
H. Abdel-Qadir, David Bobrowski, Limei Zhou, P. Austin, O. Calvillo-Argüelles, E. Amir, Douglas S. Lee, P. Thavendiranathan   +7 more
semanticscholar   +1 more source

Advanced Microfluidics for Single Cell‐Based Cancer Research

Advanced Science, EarlyView.
Cutting‐edge microfluidic platforms are transforming single‐cell cancer research. This review highlights advanced technologies, from droplet microfluidics to tumour‐chips, that enable functional and spatial single‐cell analyses. By integrating biosensing, immune components, and patient‐derived materials, these systems offer new insights into tumour ...
Adriana Carneiro, Marta Aranda Palomer, Margarida Esteves, Carolina Rodrigues, José Maria Fernandes, Francisca Oliveira, Alexandra Teixeira, Carlos Honrado, Lorena Dieguez, Sara Abalde‐Cela, Miguel Xavier   +10 more
wiley   +1 more source

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

Scientific Reports, 2023
The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and investigate the predictors of complete response.
Izzet Dogan, Esra Aydin, Nijat Khanmammadov, Nail Paksoy, Pinar Saip, Adnan Aydiner   +5 more
doaj   +1 more source

Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation

Molecular Cancer, 2020
Although trastuzumab provides significant clinical benefit for HER2-positive breast cancers, responses are limited by the emergence of resistance. Recent evidence suggests that long noncoding RNAs (lncRNAs) play important roles in tumorigenesis and ...
Mingli Han, Yuanting Gu, Pengwei Lu, Jingyi Li, H. Cao, Xiang-ke Li, Xueke Qian, Chao Yu, Yunqing Yang, Xue Yang, N. Han, Dong-wei Dou, Jianguo Hu, Huaying Dong   +13 more
semanticscholar   +1 more source

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit [PDF]

British Journal of Cancer, 2018
Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab.Gene expression profiles of pre- and post-treatment tumour ...
Triulzi, Tiziana, Regondi, Viola, De Cecco, Loris, Cappelletti, Maria Rosa, Di Modica, Martina, Paolini, Biagio, Lollini, Pier Luigi, Di Cosimo, Serena, Sfondrini, Lucia, Generali, Daniele, Tagliabue, Elda   +10 more
openaire   +5 more sources

Advanced Image‐Guidance and Surgical‐Navigation Techniques for Real‐Time Visualized Surgery

Advanced Science, EarlyView.
This review comprehensively summarizes advances in surgical navigation, covering both established and emerging intraoperative imaging technologies. It highlights mechanisms, advantages, limitations, and clinical applications, while emphasizing interdisciplinary collaboration.
Xiaoxiao Fan, Xiaolong Liu, Qiming Xia, Guoqiao Chen, Jiaxi Cheng, Zhaoqi Shi, Yifeng Fang, Parikshit Asutosh Khadaroo, Jun Qian, Hui Lin   +9 more
wiley   +1 more source

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study

Oncology and Therapy
Introduction This study evaluated the pharmacokinetic (PK) equivalence between BP02 (a proposed trastuzumab biosimilar) and the reference trastuzumab approved in the EU (EU-trastuzumab) and the US (US-trastuzumab).
Christian Schwabe, Chris Wynne, Dayaker Reddy Dyapa, Arpitkumar Prajapati, Disha Dadke   +4 more
doaj   +1 more source

Adaptive immunity in cancer immunology and therapeutics. [PDF]

, 2014
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core   +2 more sources